medmix shareholders approve all proposals at annual general meeting

28 April 2023

At today’s annual general meeting (AGM) of medmix Ltd, shareholders approved all proposals of the Board of Directors. Rob ten Hoedt was newly elected as Chairman. medmix will pay an ordinary dividend of CHF 0.50 per share to shareholders.

medmix shareholders approved all proposals of the company’s Board of Directors at its AGM 2023. The shareholders approved the medmix Annual Report 2022, including the business review, the financial statements of medmix Ltd and the consolidated financial statements 2022 as well as the appropriation of the annual result.

An ordinary dividend of CHF 0.50 per share will be paid out on May 05, 2023. In addition, the shareholders approved the medmix compensation report in a consultative vote and discharge was granted to all members of the Board of Directors and the Executive Committee. The remuneration limits for the Board of Directors concerning the period from AGM 2023 to AGM 2024, and for the Executive Committee for the financial year 2024, were authorized.

Rob ten Hoedt was newly elected as Chairman of the Board of Directors. As previously announced, Greg Poux-Guillaume did not stand for re-election as Chairman as he took over the position of Chief Executive Officer and Chair of the Board of Management at Akzo Nobel last year. The shareholders confirmed all members of the Board and the Compensation Committee standing for re-election. David Metzger was newly elected to the Compensation Committee. KPMG was confirmed as auditor and Proxy Voting Services was re-elected as the independent proxy. The shareholders also approved all proposed revisions to the Articles of Association.

The minutes of the AGM 2023 will be published shortly on

Key dates in 2023

July 20, 2023
Half-year results 2023

About medmix

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of around 2’100 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX).


Media Relations: Peter Trampert, Senior Communications Manager

Investor Relations: Sheel Gill, Head of Investor Relations

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.